Vaccines
More than 33 million people worldwide live with HIV (World Health Organization, 2009). Currently, there is no vaccine available to prevent HIV infection. Antiretroviral therapy can control progression to AIDS but cannot cure or thwart spread of the disease. For every person that begins treatment, about three more become infected. Historically, vaccines have impacted significantly the spread of infectious diseases such as smallpox, polio, measles, and yellow fever. Similarly, HIV vaccines represent the best long-term hope for ending the HIV pandemic and HIV vaccine research is a top priority for NIAID.
Special Announcements
Access to Specimens from Thai Phase III HIV Vaccine Trial (RV 144)
NIAID ARRA Funds to Accelerate High-Quality Research
Awards for B-Cell Immunology Program
Latest News
Statement: HIV Vaccine Awareness Day, 2012 | En Español—May 14, 2012
Possible Clues Found to Why HIV Vaccine Showed Modest Protection—April 4, 2012
Media Availability: Experimental Vaccine Partially Protects Monkeys from HIV-Like Infection—Jan. 4, 2012
National HIV Vaccine Awareness Day | En Español—May 11, 2011
From Our Partners
Center for HIV/AIDS Immunology (CHAVI) 2009: Understanding Early Events in HIV Infection
The Early Career Investigator (ECI) Scholar Award: Pilot Studies to Advance Non-Human Primate Models in Support of HIV Vaccine Clinical Research in FY 2010
From Recent Meetings
Functional Glycomics and HIV Vaccine Design (PDF), April 30-May 1, 2012. Summary available at Functional Glycomics in HIV Vaccine Design Workshop
Keystone Symposia 2009—New Discoveries Provide Insight into Protective Immune Responses to HIV
AIDS Vaccine 2008—New Discoveries Energize the HIV Vaccine Field
back to top
